Intervention of interest:

  • darolutamide (Nubequa®, Bayer Healthcare LLC)

ICER will publish a Special Report on Nubequa® (darolutamide, Bayer Healthcare LLC) for the treatment of prostate cancer. This report will be submitted to the Centers for Medicare & Medicaid Services (CMS) as part of the 2027 public comment process defined in CMS guidance on Medicare Drug Price Negotiations for price applicability year 2029.

For more information please contact [email protected].

ICER STAKEHOLDER OUTREACH LIST

ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.

  • Astellas
  • Bayer Healthcare LLC
  • Cancer Support Community
  • Jannsen Biotech
  • Zero Prostate Cancer

The following is a list of organizations from which ICER has requested input. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review:

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.